Back to School Report Card: 10 New Health Lessons

Slideshow

Counsel patients and parents on how best to prepare--click through these slides for the latest on school-related health issues.

As the start of the new school year approaches, parents face an ever-growing array of challenges to the health of their children, everything from postconcussion symptom spikes to cyberbullying.Click on the slideshow above for the latest on back-to-school health issues so you can counsel your patients on how best to prepare.

Recent Videos
Primary Care is the Answer to the Migraine Care Gap, Says Headache Specialist
Related Content
Nonopioid Analgesic Pilavapadin Advances to Phase 3 for Diabetic Neuropathy / image credit ©fotogurmespb/stock.adobe.com

Nonopioid Analgesic Pilavapadin Advances to Phase 3 for Diabetic Neuropathy

Grace Halsey
March 3rd 2025
Article

The investigational once-daily oral analgesic, a potent inhibitor of a novel target for neuropathic pain, achieved meaningful pain reduction vs placebo.

Obesity & Pain Management: A Primary Viewpoints Podcast

Obesity & Pain Management: A Primary Viewpoints Podcast

Sydney Jennings
April 27th 2023
Podcast

In our latest episode, an obesity medicine physician explains the importance of a comprehensive plan to manage chronic pain in patients with obesity.

Investigational Nonopioid Beats Placebo in Phase 3 Trial: Daily Dose / image credit: ©New Africa/AdobeStock

Investigational Nonopioid Beats Placebo in Phase 3 Trial: Daily Dose

Sydney Jennings
February 12th 2025
Article

Your daily dose of the clinical news you may have missed.

Primary Viewpoints Episode 19: Mobile Health Technology for Chronic Pain Management

Primary Viewpoints Episode 19: Mobile Health Technology for Chronic Pain Management

Sydney Jennings
September 29th 2022
Podcast

"Primary Viewpoints," a podcast from Patient Care Online, brings you an exclusive interview with Lynn Webster, MD, past president of the American Academy of Pain Medicine.

FDA Approves Nonopioid Journavx for Acute Pain: Daily Dose / image credit: ©New Africa/AdobeStock

FDA Approves Nonopioid Journavx for Acute Pain: Daily Dose

Sydney Jennings
February 10th 2025
Article

Your daily dose of the clinical news you may have missed.

Investigational Nonopioid Cebranopadol Meets Primary Endpoint in Pivotal Phase 3 ALLEVIATE-1 Clinical Trial / image credit ©Justlight AI/stock.adobe.com

Investigational Nonopioid Cebranopadol Meets Primary Endpoint in Pivotal Phase 3 ALLEVIATE-1 Clinical Trial

Grace Halsey
January 29th 2025
Article

Cebranopadol developer Tris Pharma expects to submit an NDA to the FDA for the dual-NMR agonist to treat moderate-to-severe acute pain later this year.

© 2025 MJH Life Sciences

All rights reserved.